View in EDS

DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.

Saved in:
Bibliographic Details
Title: DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Authors: Muik A; BioNTech SE, Mainz, Germany., Adams 3rd HC; Genmab US Inc, Plainsboro, New Jersey, USA., Gieseke F; BioNTech SE, Mainz, Germany., Altintas I; Translational Research and Precision Medicine, Genmab BV, Utrecht, The Netherlands., Schoedel KB; BioNTech SE, Mainz, Germany., Blum JM; Genmab US Inc, Plainsboro, New Jersey, USA., Sänger B; BioNTech SE, Mainz, Germany., Burm SM; Translational Research and Precision Medicine, Genmab BV, Utrecht, The Netherlands., Stanganello E; TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany., Verzijl D; Translational Research and Precision Medicine, Genmab BV, Utrecht, The Netherlands., Spires VM; Genmab US Inc, Plainsboro, New Jersey, USA., Vascotto F; TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany., Toker A; BioNTech SE, Mainz, Germany., Quinkhardt J; BioNTech SE, Mainz, Germany., Fereshteh M; Genmab US Inc, Plainsboro, New Jersey, USA., Diken M; BioNTech SE, Mainz, Germany., Satijn DPE; Genmab BV, Utrecht, The Netherlands., Kreiter S; BioNTech SE, Mainz, Germany., Ahmadi T; Experimental Medicine, Genmab US Inc, Plainsboro, New Jersey, USA., Breij ECW; Translational Research and Precision Medicine, Genmab BV, Utrecht, The Netherlands., Türeci Ö; BioNTech SE, Mainz, Germany., Sasser K; Genmab US Inc, Plainsboro, New Jersey, USA., Sahin U; BioNTech SE, Mainz, Germany.; TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany., Jure-Kunkel M; Genmab US Inc, Plainsboro, New Jersey, USA mjk@genmab.com.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jun; Vol. 10 (6).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2021-004322